logo-loader

ImmuPharma & Cenkos flag positive Lupuzor trial

Last updated: 11:16 28 Jan 2013 EST, First published: 12:16 28 Jan 2013 EST

Dimitri Dimitriou, CEO at ImmuPharma (LON:IMM) and Biotech Analyst at Cenkos, Navid Malik discuss the news from CNRS, ImmuPharma's key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor. Highlighting the results of a recent study which confirm the effectiveness of the Lupuzor peptide P140.

ImmuPharma "absolutely delighted" to push on with new clinical trial

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion...

on 06/27/2023